Michael Harty (Clare, Independent) | Oireachtas source

This morning the Oireachtas health committee published a report on orphan drugs, of which Respreeza is one drug. It is a summary of three meetings which we held on orphan drugs. Orphan drugs are different from other drugs, yet the process of looking at them is the same. They need to be treated differently. The quality process of comparing cost-benefit analysis needs to change. Undoubtedly, legislation will be required to change how orphan drugs are treated. In the meantime, I believe the quality, cost-benefit analysis needs to change for drugs such as Respreeza, Translarna and Kuvan which is forphenylketonuria.

See this speech in context